AGS 67E

Drug Profile

AGS 67E

Alternative Names: AGS67E

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agensys
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia; Lymphoid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 11 Dec 2017 AGS 67E is still in phase I trials for Lymphoid leukaemia, Hairy cell leukaemia, Chronic lymphocytic leukaemia and Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA and Canada (Astellas Pharma pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hairy-cell-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top